Chronic myelogenous leukaemia (CML): an update

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Chronic myelogenous leukemia (CML) management has significantly evolved.
• Imatinib mesylate is now standard therapy for newly diagnosed CML patients.
• Treatment efficacy varies between early and advanced CML phases.

Purpose of the Study:

• To review the current management strategies for CML.
• To assess the efficacy and limitations of imatinib mesylate therapy.
• To identify patient subgroups potentially benefiting from allogeneic stem cell transplantation (SCT).

Main Methods:

• Review of current clinical practices and published data on CML management.
• Analysis of response rates (hematological and cytogenetic) to imatinib therapy.
• Identification of criteria for considering alternative treatments like SCT.

Main Results:

• High rates of complete hematological remission (CHR) and complete cytogenetic response (CGR) observed in early chronic phase CML with imatinib.
• Lower response rates for advanced CML phases (accelerated and blast crisis).
• Specific criteria identified for considering SCT, including failure to achieve response, relapse, or advanced disease stage.

Conclusions:

• Imatinib mesylate is highly effective for early CML, but long-term molecular positivity necessitates ongoing treatment.
• Allogeneic SCT remains a crucial option for specific patient groups with CML.
• Further research is needed to identify high-risk patients and understand imatinib resistance mechanisms.